Literature DB >> 30894065

Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Hui-Fang Zhu1,2,3, Xu-Hui Zhang4, Chuan-Sha Gu1,2,3, Yan Zhong1, Ting Long1, Yi-Dan Ma1, Zhi-Yan Hu1,2,3, Zu-Guo Li1,2,3, Xiao-Yan Wang1,2,3.   

Abstract

Nontumour cells in the tumour microenvironment, especially fibroblasts, contribute to tumour progression and metastasis. The occurrence and evolution of colorectal cancer (CRC) is closely related to cancer-associated fibroblasts (CAFs). The aim of this work was to evaluate the effects of the growth factors and cytokines secreted by CAFs on CRC progression. The secreted cytokines were examined in CAFs by Human Cytokine Antibody array. We screened 37 differentially secreted cytokines in the culture supernatants of CAFs and NFs. CLEC3B, attractin, kallikrein 5 and legumain were selected for further verification. CLEC3B was more highly expressed in the stroma of CRC tissues than the other 3 cytokines. Immunohistochemistry revealed that CLEC3B expression was associated with serosal invasion by CRC. Patients with co-expression of CLEC3B and α-SMA had worse survival outcomes than those with only CLEC3B or α-SMA expression. CLEC3B secreted from CAFs may promote tumour migration. Knockdown of endogenous CLEC3B in CAFs markedly decreased CRC cell migration, while recombinant human CLEC3B clearly promoted CRC cell migration and actin remodelling. In conclusion, our findings suggest that CAFs promote the CRC cell migration and skeletal reorganization by secreting CLEC3B. CLEC3B might be a potential therapeutic molecule for CRC treatment.

Entities:  

Keywords:  CLEC3B; Cancer-associated fibroblasts (CAFs); colorectal cancer (CRC); migration; α-SMA

Year:  2019        PMID: 30894065      PMCID: PMC6606033          DOI: 10.1080/15384047.2019.1591122

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  35 in total

1.  Specificity determinants in the interaction of apolipoprotein(a) kringles with tetranectin and LDL.

Authors:  Nigel R Caterer; Jonas H Graversen; Christian Jacobsen; Søren K Moestrup; Bent W Sigurskjold; Michael Etzerodt; Hans C Thøgersen
Journal:  Biol Chem       Date:  2002-11       Impact factor: 3.915

2.  Colorectal cancer (CRC) continues to be a major public health problem in the United States and throughout the world.

Authors:  Edward Chu
Journal:  Cancer J       Date:  2010 May-Jun       Impact factor: 3.360

Review 3.  From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation.

Authors:  Charlotte Servais; Neta Erez
Journal:  J Pathol       Date:  2012-11-20       Impact factor: 7.996

4.  Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

Authors:  A Brunner; C Ensinger; M Christiansen; S Heiss; I Verdorfer; G Mikuz; A Tzankov
Journal:  Virchows Arch       Date:  2007-04-13       Impact factor: 4.064

5.  Tetranectin expression in gastric adenocarcinomas.

Authors:  D L Arvanitis; E F Kamper; L Kopeikina; A Stavridou; M N Sgantzos; V Kallioras; E Athanasiou; P Kanavaros
Journal:  Histol Histopathol       Date:  2002-04       Impact factor: 2.303

6.  Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects.

Authors:  Lei Shangguan; Xinyu Ti; Ulf Krause; Bo Hai; Yanqiu Zhao; Zhenhua Yang; Fei Liu
Journal:  Stem Cells       Date:  2012-12       Impact factor: 6.277

7.  Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma.

Authors:  Mee Lee Looi; Saiful Anuar Karsani; Mariati Abdul Rahman; Ahmad Zailani Hatta Mohd Dali; Siti Aishah Md Ali; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  J Biosci       Date:  2009-12       Impact factor: 1.826

8.  Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon.

Authors:  Yoshinao Kikuchi; Takeshi G Kashima; Takashi Nishiyama; Kazuhiro Shimazu; Yasuyuki Morishita; Masashi Shimazaki; Isao Kii; Hisanaga Horie; Hideo Nagai; Akira Kudo; Masashi Fukayama
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

9.  Clinical implications of fibroblast activation protein in patients with colon cancer.

Authors:  Leonard R Henry; Hyung-Ok Lee; John S Lee; Andres Klein-Szanto; Perry Watts; Eric A Ross; Wen-Tien Chen; Jonathan D Cheng
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

10.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

View more
  12 in total

1.  A 3-mRNA-based prognostic signature of survival in oral squamous cell carcinoma.

Authors:  Ruoyan Cao; Qiqi Wu; Qiulan Li; Mianfeng Yao; Hongbo Zhou
Journal:  PeerJ       Date:  2019-07-31       Impact factor: 2.984

Review 2.  Fibroblast Subsets in Intestinal Homeostasis, Carcinogenesis, Tumor Progression, and Metastasis.

Authors:  Hao Dang; Tom J Harryvan; Lukas J A C Hawinkels
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

3.  Atractyloside targets cancer-associated fibroblasts and inhibits the metastasis of colon cancer.

Authors:  Lu Qi; Fuyao Song; Yue Han; Ying Zhang; Yanqing Ding
Journal:  Ann Transl Med       Date:  2020-11

4.  Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients.

Authors:  Xiaolong Wang; Chen Li; Tong Chen; Wenhao Li; Hanwen Zhang; Dong Zhang; Ying Liu; Dianwen Han; Yaming Li; Zheng Li; Dan Luo; Ning Zhang; Qifeng Yang
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

Review 5.  Fundamental and Clinical Applications of Materials Based on Cancer-Associated Fibroblasts in Cancers.

Authors:  Jingtian Mu; Shengtao Gao; Jin Yang; Fanglong Wu; Hongmei Zhou
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 6.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

7.  Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation.

Authors:  Ying Wu; Yu-Mei Chang; Gerry Polton; Anneliese J Stell; Balazs Szladovits; Michael Macfarlane; Laureen M Peters; Simon L Priestnall; Nicholas J Bacon; Kelvin Kow; Sarah Stewart; Eshita Sharma; Michelle R Goulart; John Gribben; Dong Xia; Oliver A Garden
Journal:  Front Oncol       Date:  2020-03-06       Impact factor: 6.244

8.  CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment.

Authors:  Jiaxing Sun; Tian Xie; Muhammad Jamal; Zhenbo Tu; Xinran Li; Yingjie Wu; Jingyuan Li; Qiuping Zhang; Xiaoxing Huang
Journal:  Cancer Cell Int       Date:  2020-04-01       Impact factor: 5.722

9.  Adipogenic function of tetranectin mediated by enhancing mitotic clonal expansion via ERK signaling.

Authors:  Seulgi Go; Jihyun Park; Safikur Rahman; Juno Jin; Inho Choi; Jihoe Kim
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

Review 10.  The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment.

Authors:  Vladimir Mulens-Arias; José Manuel Rojas; Domingo F Barber
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.